** Shares of cancer therapy maker Legend Biotech up about 8% at $46.80 before the bell
** Board of Genscript , a key shareholder of LEGN, has "resolved to deconsolidate the Legend Group", the life sciences firm said on Tuesday
** Genscript said that after the deconsolidation, it will account for its investment in LEGN using equity method
** Genscript expects to recognize a one-time gain related to the deconsolidation
** As of Dec. 31, 2023, Genscript owned about 174.5 million shares of LEGN
** As of last close, LEGN down about 28% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。